Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin
At present, voriconazole (VOR) is the drug of first choice for treating invasive pulmonary aspergillosis (IPA). However, particularly in advanced stages of disease and in the severely immunocompromised host, the mortality remains substantial. The combination of VOR with an echinocandin may improve the therapeutic outcome. We investigate here whether combining VOR and anidulafungin (ANI) in advanced IPA in transiently neutropenic rats results in a higher therapeutic efficacy. Since VOR is metabolized more rapidly in rodents than in humans, dosage adjustment for VOR is necessary to obtain an area under the plasma concentrationtime curve (AUC) in rodents that is equivalent to that of humans. In this study, the pharmacokinetics of VOR and ANI in rats were elucidated, and dosage schedules were applied that produced AUCs similar to those of humans. The developed dose schedules were well tolerated by the rats, without effects on renal and hepatic functions. VOR showed excellent efficacy in early IPA (100% rat survival). In advanced IPA, VOR was less efficacious (50% rat survival), whereas a significant decrease in galactomannan concentrations in lungs and sera was found in surviving rats. ANI administered in advanced IPA resulted in 22% rat survival, and the serum concentrations of fungal galactomannan were slightly but not significantly decreased. The addition of ANI to VOR did not result in significantly increased therapeutic efficacy in advanced IPA, resulting in 67% rat survival and a significant decrease in galactomannan concentration in serum. In conclusion, VOR monotherapy is therapeutically effective in the treatment of advanced-stage IPA and superior to the use of ANI. Combining both agents does not significantly improve the therapeutic outcome.
|Keywords||Aspergillus fumigatus, Michaelis Menten kinetics, alanine aminotransferase, amphotericin B deoxycholate, anidulafungin, animal experiment, animal model, antifungal activity, antifungal susceptibility, area under the curve, article, aspartate aminotransferase, controlled study, creatinine, drug choice, drug clearance, drug dose increase, drug efficacy, drug half life, drug monitoring, drug safety, female, galactomannan, kidney function test, liver function test, loading drug dose, lung aspergillosis, maximum tolerated dose, minimum inhibitory concentration, monotherapy, neutropenia, nonhuman, priority journal, rat, statistical analysis, survival rate, treatment duration, voriconazole|
|Persistent URL||dx.doi.org/10.1128/AAC.01556-08, hdl.handle.net/1765/16528|
|Journal||Antimicrobial Agents and Chemotherapy|
van de Sande, W.W.J, Mathôt, R.A.A, ten Kate, M.T, van Vianen, W, Tavakol, M, Rijnders, B.J.A, & Bakker-Woudenberg, I.A.J.M. (2009). Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrobial Agents and Chemotherapy, 53(5), 2005–2013. doi:10.1128/AAC.01556-08